SCHEMBL15094151

SCHEMBL15094151

Cn1c(=O)n(Cc2ccc(F)cc2)c(=O)c2cc(C(=O)c3ncc4ccccn34)ccc21

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
HDAC1 Q13547 4/20 0.42
HPD P32754 2/20 0.42
HDAC11 Q96DB2 3/20 0.42
HDAC8 Q9BY41 3/20 0.42
HDAC6 Q9UBN7 3/20 0.42
PKM P14618 3/20 0.40
PARG Q86W56 3/20 0.40
USP1 O94782 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TP53 P04637 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
MITF O75030 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
PAX8 Q06710 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14916199 0.84 MMP13 (0.47) MMP13SLC22A8HDAC1HPDHDAC11
SCHEMBL19206316 0.81 MMP13 (0.41) MMP13SLC22A8HDAC1HPDHDAC11
SCHEMBL15016914 0.80 MMP13 (0.41) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL14916111 0.80 PKM (0.44) MMP13SLC22A8HDAC1HDAC11HDAC8
Hydrochloric Acid SCHEMBL14916909 0.80 PKM (0.44) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL15016935 0.79 MMP13 (0.41) MMP13SLC22A8HDAC1HPDHDAC11
SCHEMBL322594 0.79 MMP13 (0.46) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL6238935 0.77 MMP13 (0.61) MMP13SLC22A8HDAC1HPDHDAC11
SCHEMBL322222 0.77 HDAC1 (0.41) MMP13SLC22A8HDAC1HDAC11HDAC8
SCHEMBL15094059 0.76 KDM4E (0.40) MMP13SLC22A8HDAC1HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US claimed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP claimed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US claimed
EP-2800566-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2014-11-12 EP claimed
WO-2013102860-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2013-07-11 WO claimed
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US disclosed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 MMP13 3718/4885SLC22A8 775/4885HDAC1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.